Celldex Therapeutics has been granted a patent for methods involving antibodies that target the KIT receptor tyrosine kinase to manage eosinophil or mast cell related disorders, including those affecting the nervous system. The patent specifically covers the treatment of eosinophil-related gastrointestinal disorders using a monoclonal antibody. GlobalData’s report on Celldex Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Celldex Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Celldex Therapeutics's grant share as of May 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibody for treating eosinophil related gastrointestinal disorders
A recently granted patent (Publication Number: US11987626B2) discloses a method for protecting against, treating, or managing eosinophil-related disorders in the gastrointestinal tract caused by eosinophils responding to allergens. The method involves administering a monoclonal antibody that specifically binds to a human KIT receptor with defined sequences for the light chain variable region (VL) and heavy chain variable region (VH).
The method outlined in the patent is aimed at treating eosinophil-related disorders in human subjects by administering a therapeutically effective amount of a monoclonal antibody, which can be humanized and contains specific VL and VH sequences. The patent also specifies the option of treating both adult and pediatric patients with the antibody targeting the human KIT receptor. This innovative approach offers a targeted therapeutic solution for managing eosinophil-related disorders in the gastrointestinal tract, providing a potential breakthrough in the treatment of such conditions.
To know more about GlobalData’s detailed insights on Celldex Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
